pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

3,437 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1860Endpoints1443Fierce Biotech764BioSpace752BioPharma Dive545raps249onclive165fda recalls
therapy area
allOncology12874Rare Disease3326Immunology3010Cardiology2845Hematology2290Pulmonology2252Vaccines
  • AI bio startup Boltz secures $110 million Series A as AI drug design platform usage surges
    Boltz, an artificial‑intelligence driven biotech startup, announced a $110 million Series A financing round less than a year after emerging from stealth with an initial $28 million investment. The…
    Endpoints · 4h agoDealPositive↗ source
  • FDA issues complete response letter rejecting Summit Therapeutics' lung cancer drug
    The U.S. Food and Drug Administration released a complete response letter that rejects Summit Therapeutics' lung cancer candidate, providing the agency’s detailed reasons for the decision. The age…
    STAT · 1h agoCRLNegative↗ source
← prev
page 1 of 138
next →
118
fda medwatch114
globenewswire health73
fda press61
1852
Psychiatry & CNS1230
Ophthalmology1131
Endocrinology & Metabolism806
Pain790
Nephrology783
  • Pfizer licenses three in vivo CAR-T assets from Starna for $330 million to target autoimmune disease outside Greater China
    Pfizer announced a licensing agreement with Starna Therapeutics, a Chinese biotech, to acquire exclusive rights to three pre-IND in vivo CAR-T programs aimed at autoimmune diseases. Under the deal…
    Endpoints · 3h agoDealPositive↗ source
  • Merck halts development of BTK inhibitor acquired in $2.7 billion ArQule purchase
    Merck announced it is stopping work on nemtabrutinib, a Bruton's tyrosine kinase (BTK) inhibitor. The drug was the primary asset that motivated Merck’s 2019 acquisition of ArQule for $2.7 billion.…
    Endpoints · 4h agoDealNegative↗ source
  • Biogen's low-dose tau drug shows greater slowing of Alzheimer’s progression after two years
    Biogen reported new data on its experimental tau-reducing therapy diranersen, showing that the lowest dose continued to slow Alzheimer’s disease progression after nearly two years of treatment. Th…
    Endpoints · 15h agoPositive readoutPositive↗ source
  • White House withdraws Trump nominee Heidi Overton from FDA commissioner consideration amid Senate doubts
    The White House announced it has pulled Heidi Overton, the Trump administration’s nominee to serve as commissioner of the Food and Drug Administration. Overton’s nomination had been moving through…
    Endpoints · 15h agoRegulatoryNegative↗ source
  • Trump administration withdraws Heidi Overton’s FDA nomination amid Senate support concerns
    The Trump administration has pulled the nomination of Heidi Overton to become the U.S. Food and Drug Administration commissioner, saying she lacked sufficient backing to win Senate confirmation. T…
    STAT · 1h agoRegulatoryNeutral↗ source
  • Debate Over Medical School Structure Emerges as U.S. Loses Measles Elimination Status
    A discussion is unfolding about whether the traditional four‑year medical school model should be broken into separate components. The idea was voiced by a medical student who asked if every part of…
    STAT · 3h agoNegative↗ source
  • Loss of Senate Appropriations Chair Susan Collins could weaken scientists’ fight against new research oversight rule
    Senator Susan Collins, the Republican chair of the Senate Appropriations Committee, was defeated in her re‑election, ending her role as the most prominent GOP ally for science advocates. Scientist…
    STAT · 6h agoRegulatoryNegative↗ source
  • White House withdraws Heidi Overton's nomination to lead the FDA amid Senate Republican concerns
    The White House announced it is withdrawing its nominee, Heidi Overton, for FDA commissioner. Overton, a preventive care physician who previously served in the Trump administration, faced resistan…
    STAT · 15h agoRegulatoryNegative↗ source
  • Opinion calls for impeachment of Health Secretary Robert F. Kennedy Jr. over anti‑vaccine stance
    Professor Paul Knoepfler, a cell‑biology faculty member at UC Davis, argues that the post‑midterm political climate creates a window to remove Health and Human Services Secretary Robert F. Kennedy…
    STAT · 6h agoNegative↗ source
  • Opinion argues that traditional four-year medical schools may be outdated for pre-clerkship training
    Alex Serafini, a fourth‑year medical student at Icahn School of Medicine, contributes to a new First Opinion series that questions the structure of modern medical education. He notes that over the…
    STAT · 6h agoNeutral↗ source
  • STAT+: Cassidy rejects Trump’s pick to lead NSF, saying he failed to ‘stand up for science’
    Bill Cassidy's rejection of Jim O'Neill comes shortly after the White House pulled FDA commissioner nominee Heidi Overton.
    STAT · 43m ago↗ source
  • Dispatches from Jefferies: Latent Labs on AI, Relay’s PI3Kα ambitions and Biohaven’s protein degrader approach
    LONDON — Long queues snaked outside the iconic Waldorf Hilton on Monday morning at the 17th Jefferies Global Healthcare Conference as attendees jostled to pick up registration badges — only to be u…
    Endpoints · 50m ago↗ source
  • FDA Approves First Drug Shown to Help Patients with Infantile-Onset Niemann-Pick Disease Type C Live Longer
    FDA approved Lembaz (adrabetadex) injection, the first treatment shown to help people with a severe form of Niemann-Pick disease type C (NPC) live longer.
    fda press · 21h agoApprovalPositive↗ source
  • Isomorphic Labs lands record $5 billion Series C, marking biggest private biotech raise ever
    Isomorphic Labs, a Google-backed biotech company, announced a $5 billion Series C financing round. The round, completed just six months after a $2.1 billion raise, is the largest private capital r…
    Endpoints · 23h agoDealPositive↗ source
  • Roche secures FDA approval for giredestrant, its first SERD for advanced breast cancer
    Roche announced that its experimental breast cancer drug giredestrant received FDA approval for treatment of patients with late‑stage disease. The approval places Roche into the selective estrogen…
    Endpoints · 1d agoApprovalPositive↗ source
  • GSK receives accelerated FDA approval for oral lung cancer drug neladalkib
    GSK announced that the U.S. Food and Drug Administration granted accelerated approval to its oral lung cancer therapy neladalkib. The approval comes as part of the company's $10.6 billion acquisit…
    Endpoints · 20h agoApprovalPositive↗ source
  • FDA approves Roche's new breast cancer drug, poised to become its top-selling product
    The U.S. Food and Drug Administration has granted approval to a new breast cancer therapy developed by Roche. This clearance paves the way for the drug's market launch. Roche says the medication c…
    STAT · 1d agoApprovalPositive↗ source
  • Sellas' galinpepimut-S cuts death risk by 41% in Phase 3 AML trial
    Sellas Life Sciences announced that its experimental immunotherapy galinpepimut-S achieved a 41% reduction in risk of death for patients with advanced acute myeloid leukemia in a Phase 3 trial. Th…
    STAT · 1d agoPositive readoutPositive↗ source
  • Beren Therapeutics secures FDA approval for Lembaz to treat infantile-onset Niemann-Pick disease type C
    Beren Therapeutics announced that the U.S. Food and Drug Administration has approved its drug Lembaz for the treatment of infantile‑onset Niemann‑Pick disease type C, a rare and severe pediatric co…
    Endpoints · 19h agoApprovalPositive↗ source
  • Sellas Life Sciences reports Phase 3 success for AML vaccine galinpepimut-S
    Sellas Life Sciences announced on Tuesday that its experimental cancer vaccine achieved a positive outcome in a Phase 3 study. The trial enrolled patients with a specific form of acute myeloid leu…
    Endpoints · 21h agoPositive readoutPositive↗ source
  • Capsida proposes new monkey testing framework after fatal gene therapy trial for brain disease
    Researchers presented investigations into a patient death that occurred in a gene therapy trial for a brain disease, which had raised concerns in the field. While the exact cause of death was not…
    STAT · 1d agoNegative readoutNegative↗ source
  • FDA flags VEGF safety concern in Summit Therapeutics' rejected bispecific cancer drug ivonescimab
    The U.S. Food and Drug Administration identified a potential safety issue while reviewing ivonescimab, a bispecific cancer therapy being developed by Summit Therapeutics and Akeso. The agency’s co…
    Endpoints · 19h agoRegulatoryNegative↗ source
  • FDA unveils Global Reliance Disclosure Program to speed international drug approvals
    The FDA announced the Global Reliance Disclosure Program (GRDP) on November 17, 2026, describing it as a new effort to share its drug and biologic approval packages with other health authorities.…
    fda press · 19h agoRegulatoryPositive↗ source